Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE:002399)

China flag China · Delayed Price · Currency is CNY
9.66
-0.23 (-2.33%)
Jul 21, 2026, 3:04 PM CST
Market Cap12.87B -24.2%
Revenue (ttm)5.42B +2.1%
Net Income380.47M -41.3%
EPS0.26 -41.3%
Shares Out 1.47B
PE Ratio37.25
Forward PE16.66
Dividend0.15 (1.47%)
Ex-Dividend DateJun 18, 2026
Volume6,450,798
Open10.25
Previous Close9.89
Day's Range9.55 - 10.25
52-Week Range8.50 - 14.34
Beta0.31
Analystsn/a
Price Targetn/a
Earnings DateAug 29, 2026

About SHE:002399

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium APIs. It also provides molecule biologics CDMO services, which include... [Read more]

Sector Healthcare
Founded 1998
Employees 2,150
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002399
Full Company Profile

Financial Performance

In 2025, SHE:002399's revenue was 5.48 billion, an increase of 3.75% compared to the previous year's 5.28 billion. Earnings were 349.49 million, a decrease of -45.96%.

Financial Statements